LoQus23 Therapeutics anuncia um financiamento de 35 milhões de libras para fazer avançar um novo medicamento destinado a inibir a expansão somática na doença de Huntington
Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy type 1 and similar triplet repeat expansion diseases, today announces Ler mais...